Conference Day 1 | 3rd Hippo Pathway Targeted Drug Development Summit

CONFERENCE DAY ONE

8:00 am Digital Networking Room Opens

8:25 am Chair’s Opening Remarks

Satu Juhila Project Leader, Orion Pharma

Developing Innovative Combination Strategies to Unlock Novel Applications of Hippo- Targeted Drugs

8:30 am Per Aspera Ad Astra: The Potential of Hippo Pathway inhibition as a Mono- & Combination Therapy Concept

Federico Mauri Priincipal Scientist, Boehringer Ingelheim

Synopsis

Download the Brochure to View the Session Details

9:00 am Panel Discussion: Advancing Hippo Pathway Combination Strategies: Exploring Current & Future Cross-Pathway Opportunities

Chenglong Li Professor, University of Florida
Wanjin Hong Chief Business Development Officer, Biomedical Research Council (BMRC) at A*STAR
Satu Juhila Project Leader, Orion Pharma
Srinivas Vinod Saladi Ph.D. Assistant Professor, Harvard Medical School

Synopsis

Download the Brochure to View the Session Details

9:45 am Morning Break & Virtual Networking

Tackling Resistance Mechanisms Driven by the Hippo Pathway to Effectively Develop Combination Strategies Against MAPK & EGFR Cancers

10:30 am Determining New Roles of the Hippo Pathway in Driving Cancer Formation, Progression & Adaptive Resistance to Inform Combination Strategies

Srinivas Vinod Saladi Ph.D. Assistant Professor, Harvard Medical School

Synopsis

Download the Brochure to View the Session Details

11:00 am Exploring Resistance Mechanisms in MAPK-Addicted Cancers: YAP Upregulation, Immune Suppression, & Innovative Combination Strategies for Hippo Pathway Targeted Drugs

Kari Kurppa Principal Investigator, Academy Reserach Fellow, University of Turku

Synopsis

Download the Brochure to View the Session Details

11:30am Lunch Break & Virtual Networking

Developing Innovative Drugs Against YAP & TEAD Through Cutting-Edge Discovery Platforms to Hit the Pathway at Multiple Nodes

Chair: Melanie Frigault, Consultant, Translational Medicine, Vincerx Pharma

1:00 pm QUANTROseq®, a Transcriptomic-Based Drug Discovery Platform to Identify Inhibitors & Degraders of Transcription Factors & Cell Signaling Regulators

Arianna Sabò Head of Research & Discovery, QUANTRO Therapeutics

Synopsis

Download the Brochure to View the Session Details

1:30 pm Advancing the Discovery & Development of a Novel YAP Degrader Against Liver Cancer

Chenglong Li Professor, University of Florida

Synopsis

Download the Brochure to View the Session Details

2:00 pm Discovery & Development of a Novel Covalent TEAD Inhibitor with Exceptional Anti-Cancer Activity & Druggability

Shirley Guo Director of Biology, BridGene Biosciences Inc.

Synopsis

Download the Brochure to View the Session Details

2:30 pm Afternoon Break & Virtual Networking

Tackling Late Discovery & Early Pre-Clinical Bottlenecks to Accelerate Your Hippo Drug into the Clinic

3:15 pm Presenting a Novel Pan TEAD Inhibitor to Treat Hippo Pathway Dysregulated Tumors

Michelle Chen CBO, Insilico Medicine

Synopsis

Download the Brochure to View the Session Details

3:45 pm Panel Discussion: Optimizing the Discovery & Development of Effective Small Molecule Drugs Against TEAD to Expedite Translation to the Clinic

Shirley Guo Director of Biology, BridGene Biosciences Inc.
Jeff Holden Head of Structural Biology, Vilya Therapeutics
Melanie Frigault Translational Medicine, Vincerx Pharma

Synopsis

Download the Brochure to View the Session Details

4:30 pm Targeting the Hippo Pathway Through GPCRs to Cure Inflammatory, Oncological & Autoimmune Conditions

Zhi Liang Chu Founder, Chief Executive Officer & Chief scientific officer, Crossignal Therapeutics

Synopsis

Download the Brochure to View the Session Details

5:00 pm Chair’s Closing Remarks & End of Day One

Melanie Frigault Translational Medicine, Vincerx Pharma